Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb.

卫材株式会社（总部：东京，首席执行官：Haruo Naito，“卫材”）今天宣布，由于百时美施贵宝内部正在进行的投资组合优先化工作，它已同意终止与百时美施贵宝的全球战略合作，共同开发和共同商业化法妥珠单抗ecteribulin（FZEC），原名MORAb-202，一种叶酸受体α（FRα）靶向抗体-药物偶联物（ADC）。

Based on the agreement, Eisai now owns all rights to FZEC and will solely conduct the global development and commercialization of the agent. Eisai will accelerate the development of the agent as a high priority with the hope to deliver it to patients as early as possible. Eisai plans to refund a part of the unused portion of the $200 million payment it received towards research and development expenses from Bristol Myers Squibb under the collaboration agreement and record the remaining as other income.FZEC is Eisai’s first ADC and is composed of Eisai’s in-house developed farletuzumab, a humanized IgG1 monoclonal antibody that binds to the FRα, and Eisai’s in-house developed anticancer agent eribulin, using an enzymatically cleavable linker.

根据该协议，卫材现在拥有FZEC的所有权利，并将全权负责代理的全球开发和商业化。卫材将优先加速该药物的开发，希望尽早将其交付给患者。卫材计划退还其根据合作协议从百时美施贵宝收到的2亿美元研发费用中未使用部分的一部分，并将剩余部分记为其他收入。FZEC是Eisai的第一个ADC，由Eisai内部开发的farletuzumab（一种与FRα结合的人源化IgG1单克隆抗体）和Eisai内部开发的抗癌剂eribulin组成，使用可酶切的接头。

Currently, three clinical studies are ongoing: Eisai’s Phase 1/2 study for solid tumors (NCT04300556), and Bristol Myers Squibb’s Phase 2 studies for ovarian, peritoneal and fallopian tube cancers (NCT05613088) and non-small cell lung cancer (NCT05577715).Eisai positions oncology as a key franchise area and aims to contribute toward the cure of cancers by exploring the depths of human biology.

目前，正在进行三项临床研究：卫材的实体瘤1/2期研究（NCT04300556），百时美施贵宝的卵巢癌，腹膜癌和输卵管癌2期研究（NCT05613088）和非小细胞肺癌（NCT05577715）。卫材将肿瘤学定位为一个关键的特许经营领域，旨在通过探索人类生物学的深度，为癌症的治疗做出贡献。

FZEC development for refractory cancers is a testament of our dedication to addressing the unmet medical needs of patients with cancer. Eisai will make continuous efforts to increase the benefits provided to patients with c.

FZEC针对难治性癌症的开发证明了我们致力于解决癌症患者未满足的医疗需求。卫材将继续努力增加为c患者提供的益处。